Micro Interventional Devices initiates 1st-in-man EU study for its Permaseal
Cardiovascular medical device company Micro Interventional Devices launched a 1st-in-man European clinical study for its Permaseal cardiac closure, a device which combines soft tissue anchors and biocompatible elastomers that form a "web" around the myocardial access site, the company said.
The study will enroll 40 patients at 5 E.U. sites, and MID expects data to be available by Q1 2013.
Symetis closes 1st-in-man trial for Acurate TF aortic bioprosthesis
Swiss medical device maker Symetis completed its 1st-in-man trial of the Acurate TF aortic bioprosthesis and delivery system, a transfemoral aortic valve replacement device.
The company initiated the CE-Mark clinical study in September and hopes the system will win CE Mark approval mid-2013.
Cappella Medical: Positive long-term results for its Sideguard Technology
Medical device maker Cappella Medical unveiled long-term results for its Sideguard coronary sidebranch stent, which is designed to protect sidebranch during treatment of bifurcation disease.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.